| Primary |
| Chronic Lymphocytic Leukaemia |
19.4% |
| B-cell Lymphoma |
13.1% |
| Prophylaxis |
10.0% |
| Plasma Cell Myeloma |
9.9% |
| Mantle Cell Lymphoma |
8.8% |
| Product Used For Unknown Indication |
7.9% |
| Non-hodgkin's Lymphoma |
7.1% |
| Lymphoma |
3.5% |
| Lymphocytic Lymphoma |
2.8% |
| Premedication |
2.8% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
2.3% |
| Hypertension |
2.3% |
| Diffuse Large B-cell Lymphoma |
2.2% |
| Small Cell Lung Cancer Stage Unspecified |
1.7% |
| Diabetes Mellitus |
1.5% |
| Chemotherapy |
1.0% |
| Leukaemic Lymphoma |
1.0% |
| Bronchitis |
0.9% |
| Infection Prophylaxis |
0.9% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
|
| Pancytopenia |
7.2% |
| Thrombocytopenia |
7.2% |
| Febrile Neutropenia |
6.4% |
| Neutropenia |
6.4% |
| Pyrexia |
6.4% |
| White Blood Cell Count Decreased |
6.4% |
| Pulmonary Embolism |
5.6% |
| Rash |
5.6% |
| Viral Infection |
5.6% |
| Lymphocyte Count Decreased |
4.8% |
| Sepsis |
4.8% |
| Neutrophil Count Decreased |
4.0% |
| Off Label Use |
4.0% |
| Pneumonia |
4.0% |
| Pneumonitis |
4.0% |
| Renal Failure |
4.0% |
| Upper Gastrointestinal Haemorrhage |
4.0% |
| Cytomegalovirus Infection |
3.2% |
| Syncope |
3.2% |
| Vomiting |
3.2% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
15.2% |
| Product Used For Unknown Indication |
12.5% |
| Non-hodgkin's Lymphoma |
11.2% |
| B-cell Lymphoma |
11.0% |
| Mantle Cell Lymphoma |
6.7% |
| Plasma Cell Myeloma |
5.5% |
| Drug Use For Unknown Indication |
4.7% |
| Prophylaxis |
4.4% |
| Lymphoma |
4.0% |
| Multiple Myeloma |
3.5% |
| Hodgkin's Disease |
3.2% |
| Breast Cancer |
3.2% |
| Lung Neoplasm Malignant |
3.2% |
| Diffuse Large B-cell Lymphoma |
2.4% |
| Hypertension |
2.1% |
| Premedication |
1.6% |
| B-cell Small Lymphocytic Lymphoma |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Acute Lymphocytic Leukaemia |
1.4% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
1.2% |
|
| Thrombocytopenia |
11.6% |
| Febrile Neutropenia |
9.4% |
| Pyrexia |
6.7% |
| Lymphocyte Count Decreased |
6.2% |
| Pneumonia |
6.2% |
| White Blood Cell Count Decreased |
6.2% |
| Vomiting |
5.3% |
| Progressive Multifocal Leukoencephalopathy |
4.9% |
| Sepsis |
4.9% |
| Death |
4.7% |
| Rash |
4.5% |
| Cytomegalovirus Infection |
4.0% |
| General Physical Health Deterioration |
4.0% |
| Platelet Count Decreased |
3.3% |
| Pulmonary Oedema |
3.3% |
| Neutrophil Count Decreased |
3.1% |
| Toxic Skin Eruption |
3.1% |
| Vasculitis |
3.1% |
| Diarrhoea |
2.7% |
| Pancytopenia |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.2% |
| Chronic Lymphocytic Leukaemia |
13.9% |
| Product Used For Unknown Indication |
13.7% |
| Non-hodgkin's Lymphoma |
10.7% |
| Multiple Myeloma |
7.2% |
| B-cell Lymphoma |
5.8% |
| Lymphoma |
5.8% |
| Plasma Cell Myeloma |
4.9% |
| Prophylaxis |
3.3% |
| Mantle Cell Lymphoma |
3.1% |
| Plasmacytoma |
2.9% |
| Chemotherapy |
2.4% |
| Hypertension |
1.9% |
| Pain |
1.9% |
| B-cell Lymphoma Recurrent |
1.5% |
| Idiopathic Thrombocytopenic Purpura |
1.3% |
| Infection Prophylaxis |
1.2% |
| Premedication |
1.2% |
| Diffuse Large B-cell Lymphoma |
1.1% |
| Lymphoplasmacytoid Lymphoma/immunocytoma |
0.9% |
|
| Progressive Multifocal Leukoencephalopathy |
18.8% |
| Thrombosis |
9.0% |
| Plasma Cell Myeloma |
6.8% |
| Osteonecrosis |
6.0% |
| Pyrexia |
6.0% |
| Death |
4.5% |
| Oesophageal Carcinoma |
4.5% |
| Thrombocytopenia |
4.5% |
| Leukopenia |
3.8% |
| Neoplasm Malignant |
3.8% |
| Renal Failure |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Movement Disorder |
3.0% |
| Pancytopenia |
3.0% |
| Pneumonia |
3.0% |
| Pulmonary Embolism |
3.0% |
| Rash |
3.0% |
| Septic Shock |
3.0% |
| Systemic Mycosis |
3.0% |
|
| Interacting |
| Chronic Lymphocytic Leukaemia |
30.0% |
| Diabetes Mellitus |
30.0% |
| Pain |
20.0% |
| Lymphoma |
10.0% |
| Unevaluable Event |
10.0% |
|
| Drug Withdrawal Syndrome |
50.0% |
| Oral Herpes |
50.0% |
|
